Status:
NO_LONGER_AVAILABLE
Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Adenocarcinoma of the Prostate
Eligibility:
MALE
18+ years
Brief Summary
This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects with prostate cancer prior to it becoming commercially available. The patient will receive bicalutamide 15...
Eligibility Criteria
Inclusion
- Patients with adenocarcinoma of the prostate
- Subjects with locally advanced, and/or metastatic prostate cancer for whom surgical castration or other medical interventions are not considered appropriate or acceptable
Exclusion
- Any known history of abnormal liver function tests
- Any severe concomitant condition that would make it undesirable, in the clinician's opinion, for the subject to participate in the trial.
- Known hypersensitivity to bicalutamide or any of the components found in bicalutamide
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00636259
Last Update
June 11 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.